ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (ANIP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ANIP · as of Sep 30, 2025
Ownership Breakdown
275
Institutional Holders
▲ 40 vs Q2
$1.87B
Total Inst. Value
▲ $579.51M vs Q2
22.73M
Shares Outstanding
freeFloat 85.61%
20.40M
13F Shares Held
▲ 647,418 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ANIP largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 2.55M | 12.85% | 12.85% | $233.48B | Nov 12, 2025 | ▼ 31.6K |
VANGUARD GROUP INC pharmaceutical preparations | 1.28M | 6.44% | 6.44% | $117.02B | Nov 7, 2025 | ▲ 116 |
STATE STREET CORP pharmaceutical preparations | 711.7K | 3.59% | 3.59% | $65.19B | Nov 14, 2025 | ▼ 4.4K |
GLOBAL ALPHA CAPITAL MANAGEMENT LTD. pharmaceutical preparations | 630.6K | 3.18% | 3.18% | $57.76B | Nov 13, 2025 | ▼ 231.5K |
UBS GROUP AG pharmaceutical preparations | 589.9K | 2.97% | 2.97% | $54.03B | Nov 13, 2025 | ▲ 185.2K |
CITADEL ADVISORS LLC pharmaceutical preparations | 580.1K | 2.92% | 2.92% | $53.14B | Nov 14, 2025 | ▲ 10.5K |
DIMENSIONAL FUND ADVISORS LP pharmaceutical preparations | 505.4K | 2.55% | 2.55% | $46.30B | Nov 12, 2025 | ▼ 48.5K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 458.0K | 2.31% | 2.31% | $41.96B | Nov 12, 2025 | ▲ 30.5K |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 450.0K | 2.27% | 2.27% | $41.22B | Nov 14, 2025 | ▼ 250.0K |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 399.1K | 2.01% | 2.01% | $36.56B | Nov 14, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
22
Increased
+2.38M shares3
New Positions
first time holders23
Decreased
−1.81M shares0
Sold Out
fully exitedNet shares change (top 50)
+569.5K
+2.38M / −1.81M
Net new holders
+2
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ANIP insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
7
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Walsh Patrick D director | May 11, 2026 | Sale | 3,973 | $80.75 | $320.8K | 48.4K | Form 4 ↗ |
Walsh Patrick D director | May 13, 2026 | Sale | 10,000 | $80.63 | $806.3K | 38.4K | Form 4 ↗ |
Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | May 12, 2026 | Sale | 459 | $79.21 | $36.4K | 38.3K | Form 4 ↗ |
Lalwani Nikhil PRESIDENT & CEO | May 11, 2026 | Sale | 55,000 | $77.57 | $4.27M | 349.9K | Form 4 ↗ |
Gutwerg Ori SVP, GENERICS | May 12, 2026 | Sale | 2,772 | $79.50 | $220.4K | 78.7K | Form 4 ↗ |
Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | May 13, 2026 | Sale | 500 | $78.16 | $39.1K | 78.4K | Form 4 ↗ |
Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Apr 13, 2026 | Sale | 500 | $77.95 | $39.0K | 78.9K | Form 4 ↗ |
Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | Mar 11, 2026 | Sale | 4,772 | $74.91 | $357.5K | 38.7K | Form 4 ↗ |
Mutz Christopher HEAD OF RARE DISEASE | Mar 13, 2026 | Sale | 3,162 | $71.64 | $226.5K | 91.3K | Form 4 ↗ |
Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Mar 13, 2026 | Sale | 500 | $72.62 | $36.3K | 79.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
ANI Pharmaceuticals, Inc. (ANIP) is primarily owned by institutional investors, who hold approximately 89.8% of total shares outstanding. Company insiders own approximately 14.39%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of ANI Pharmaceuticals, Inc. is BLACKROCK, INC., holding approximately 2.55 million shares — equal to 12.85% of outstanding shares — as of September 30, 2025.
A total of 275 institutional investors currently hold ANIP stock, with a combined institutional value of approximately $1.87 billion as of the most recent 13F filing period.
Frequently asked questions
ANIP ownershipANI Pharmaceuticals, Inc. (ANIP) is primarily owned by institutional investors, who hold approximately 89.8% of shares. The largest shareholder is BLACKROCK, INC. with a 12.85% stake. Company insiders hold 14.39%. Data sourced from SEC Form 13F as of September 30, 2025.